News | November 14, 2025
Hormone therapy for menopause gets green light from FDA
The FDA is initiating removal of the boxed warnings following a comprehensive review of the scientific literature
The FDA is initiating removal of the boxed warnings following a comprehensive review of the scientific literature
False positive rates?ranged from 0% to 41%, meaning some labs incorrectly identified bacteria that weren’t present in the sample
Nearly 1 in 3 HbA1c test results fall within the diabetic range, while 1 in 4 individuals show signs of prediabetes
OERIS offers extended antiemetic coverage through a single injection that effectively prevents both acute and delayed CINV for up to five days
While the trial fell short of demonstrating a statistically significant PFS benefit compared to chemotherapy, early data suggest a potential overall survival advantage
This approval is based on positive results from two Phase 3, global, double-blind, placebo-controlled trials
Relmada expects to initiate its Phase 3 program in the first half of 2026
The FDA setback highlights ongoing tensions between patient needs, regulatory processes, and the use of real-world evidence in evaluating treatments for rare diseases
VLA1601 is a purified and inactivated vaccine specifically designed to protect against the Zika virus
The study demonstrated strong clinical outcomes, with 94.8 per cent of subjects remaining free from major target limb amputation at one year
Subscribe To Our Newsletter & Stay Updated
